Discussion of the final data analysis comparing daratumumab plus lenalidomide, bortezomib and dexamethasone to lenalidomide, bortezomib and dexamethasone alone.
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Treatment:
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Douglas Sborov, MD.
The phase 2 GRIFFIN study investigated adding daratumumab to standard-of-care lenalidomide, bortezomib, and dexamethasone (RVD) in the autologous stem cell transplant setting. Two arms were compared: RVD induction, transplant, RVD consolidation, and lenalidomide maintenance vs daratumumab-RVD (Dara-RVD) induction, transplant, Dara-RVD consolidation, and Dara-lenalidomide maintenance. Primary end point was stringent complete response rate after consolidation. Secondary end points included response rates, minimal residual disease (MRD) negativity, progression-free survival (PFS), overall survival, safety, and quality of life. Final analysis occurred after 1 year or more of maintenance.
Ultimately, GRIFFIN showed Dara-RVD improved overall response, complete response/better, and MRD negativity rates over time vs RVD. By trial end, complete response or better rate was 83% and MRD negativity rate (10-5 threshold) was 64% with Dara-RVD. The primary end point was met. At 50-month median follow-up, Dara-RVD led to a 55% reduction in disease progression/death risk. Along with other data, Griffin set the stage for adoption of quadruplet regimens in the US and for the PERSEUS phase 3 trial powered for PFS comparing quadruplet and triplet regimens.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Assessing The Rationale Behind Triplet Regimens in RRMM
June 14th 2024During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed the long-term results of the phase 3 IKEMA study that build the rationale for use of the triplet therapy isatuximab, carfilzomib, and dexamethasone, in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Grajales-Cruz Interprets Data for Earlier- Line CAR T-Cell Therapy in R/R MM
June 8th 2024During a Case-Based Roundtable® event, Ariel F. Grajales-Cruz, MD, discussed data from the KarMMa-3 trial of idecabtagene vicleucel and real-world data on the CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Read More
Khouri Analyzes How Daratumumab-Based Quadruplet Therapy Achieves MRD States in Multiple Myeloma
June 7th 2024During a Case-Based Roundtable® event, Jack Khouri, MD, discussed data from the GRIFFIN, PERSEUS, and MASTER trials that investigated quadruplet therapy in patients with newly diagnosed multiple myeloma.
Read More